STAT July 7, 2023
The recent FDA approval of Leqembi, the latest anti-amyloid drug, is undoubtedly a breakthrough for the field, providing a new way to slow the advancement of mild cognitive impairment or early-stage Alzheimer’s disease. As a practicing geriatrician who has treated Alzheimer’s patients for more than 40 years and the co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation, I have never been more optimistic about our potential to transform how we treat and diagnose patients.
Hundreds of thousands of patients are expected to be prescribed Leqembi in the coming years, according to the drugmakers Eisai and Biogen. However, for Leqembi and other anti-amyloid therapies to become the standard of care, we need to accelerate the development, awareness, and...
Today's Sponsors
Today's Sponsor